Regeneron Pharmaceuticals has recently drawn renewed attention as investment funds, Wall Street analysts, and industry observers highlight its broad biologics pipeline, disciplined capital allocation, ...

Longleaf Partners, managed by Southeastern Asset Management, released its fourth-quarter 2025 investor letter. A copy of the ...

The Regeneron Science Talent Search 2026 finalists represent 35 schools across 15 states. They are competing for more than $1.8 million, with a top prize of $250,000 to further their scientific ...

Regeneron Pharmaceuticals, Inc. nears a key earnings report after a strong JPM Healthcare update. Click here to find out why ...

The story around Regeneron is shifting, and one big player just made it official.

On Wednesday, January 21, the Society for Science (the Society) and Regeneron announced the top 40 finalists in the Regeneron ...

Among other things, we talked about President Trump’s “most-favored nations” policy on drug pricing and why Regeneron is the ...

Regeneron Pharmaceuticals (REGN) has recently drawn attention after a period where the share price showed mixed short term ...

Regeneron Pharmaceuticals, which garnered attention in 2020 when President Donald Trump touted the company's experimental COVID-19 vaccine as a "cure," said Monday, May 19, that it will buy 23andMe's ...

Could the tide be turning for Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) after a surprising shift in analyst sentiment?

In a Q&A for Fierce Pharma Marketing’s “Rising Stars” series, Catie Matthews suggested that marketers should embrace artificial intelligence in their own lives.

Did you spit in a tube for 23andMe? If so, your genetic data may soon be handed over to a new company — Regeneron. Just four years ago, when 23andMe went public, the company was valued at $6 billion.